Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 5/20 | 0.40 |
| ▸ | GABRD | O14764 | 5/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.40 |
| ▸ | GABRE | P78334 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185189 | 0.86 | TSHR (0.43) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL24998437 | 0.83 | NAMPT (0.44) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL24574424 | 0.82 | NAMPT (0.40) | KDM4EALDH1A1HPGDPOLBGAA | |
| SCHEMBL15717868 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL2922016 | 0.78 | KDM4E (0.63) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL17169816 | 0.78 | NAMPT (0.44) | ALDH1A1CYP1A2NAMPTCBLB | |
| SCHEMBL15286376 | 0.78 | MAOB (0.45) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL6413579 | 0.77 | KDM4E (0.47) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL2251313 | 0.77 | ESR1 (0.47) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL10185196 | 0.76 | NAMPT (0.48) | KDM4EALDH1A1CYP1A2NAMPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098667-A1 | USP30 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 长春金赛药业有限责任公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4695252-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213659-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| CN-118684631-A | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors, compositions and uses thereof | 中国科学院上海药物研究所 | 2024-09-24 | — | — | CN | disclosed |
| CN-111542526-B | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| WO-2014078813-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-6858613-B2 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1476449-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003070732-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | KDM4E 3522/4885ALDH1A1 239/4885HPGD 656/4885 |
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | CYP11B2, CYP11B1, SLC10A1 | KDM4E 3176/4885ALDH1A1 1193/4885HPGD 1118/4885 |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | KDM4E 2428/4885ALDH1A1 297/4885HPGD 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.